MedPath

Polyethylene glycol

Generic Name
Polyethylene glycol
Brand Names
Bi-peglyte, Clearlax, Colyte, Gavilax, Gavilyte-C, Gavilyte-G, Gavilyte-H and Bisacodyl, Gavilyte-N, Gentlelax, Gialax, Glycolax, Golytely, Healthylax, Miralax, Moviprep, Nulytely, Peglyte, Pegylax, Plenvu, Purelax, Suflave
Drug Type
Small Molecule
CAS Number
25322-68-3
Unique Ingredient Identifier
3WJQ0SDW1A
Background

Polyethylene glycol (PEG) is a synthetic polymer produced via polymerization of ethylene oxide molecules to make joining units of ethylene glycol by an ether linkage. PEGs are water-soluble polymers that can form hydrogen bonds in a ratio of 100 water molecules per one PEG molecule. Molecular weights of PEGs vary by time of the polymerization process and the molecular weight represents the weighted average of the individual PEG molecules. PEGs differ in their physical and chemical properties depending on their molecular weight: PEGs are liquids when molecular weights are <1000 and the molecule turns to waxy solids with increasing molecular weights. The most common preparations of PEGs include PEG 3350 and PEG 400. PEGs have various applications in many fields, ranging from medical to industrial areas. PEGs have a long history of gastroenterology: PEG 3350 is a common over-the-counter osmotic laxative used to relieve occasional constipation. PEG 3350 is also used for cleansing of the colon in preparation for colonoscopy in adults.

The rationale of using PEG in gastroenterology is due to the physical properties of the compound: its potent water-binding capacity, negligible intestinal absorption with increasing molecular mass, lack of significant toxicity, and limited intestinal enzymatic degradation or bacterial metabolism all make PEG a useful therapeutic agent for the treatment of occasional constipation and bowel cleansing for preparation in colonoscopy.

Indication

Polyethylene glycol is indicated for use as an over-the-counter osmotic laxative to relieve occasional constipation. When used in combination with sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride, it is used for cleansing of the colon in preparation for colonoscopy in adults.

Associated Conditions
Chronic Constipation, Constipation, Dry Eye Syndrome (DES), Dry Eyes, Occasional Constipation
Associated Therapies
Bowel preparation therapy, Eye lubrication

Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

First Posted Date
2015-04-17
Last Posted Date
2018-06-11
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
1
Registration Number
NCT02419469
Locations
🇺🇸

University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Split-dose Versus Single-dose Polyethylene Glycol Regimen for Capsule Endoscopy

Phase 4
Conditions
Bowel Preparation
Interventions
Device: Capsule endoscopy
First Posted Date
2015-03-24
Last Posted Date
2015-03-24
Lead Sponsor
Centro Hospitalar Lisboa Ocidental
Target Recruit Count
50
Registration Number
NCT02396017
Locations
🇵🇹

Gastroenterology Department, Hospital Egas Moniz, Lisboa, Portugal

A Pilot Evaluation of an Experimental BLI4600 Formulation for Bowel Preparation in Adult Patients Undergoing Colonoscopy

Phase 2
Completed
Conditions
Bowel Preparation for Colonoscopy
Interventions
Drug: BLI4600 bowel preparation
First Posted Date
2015-03-03
Last Posted Date
2016-07-19
Lead Sponsor
Braintree Laboratories
Target Recruit Count
45
Registration Number
NCT02376465
Locations
🇺🇸

University of South Alabama, Mobile, Alabama, United States

Urotherapy vs. Urotherapy With Constipation Treatment for Children With Lower Urinary Tract Dysfunction

Phase 4
Withdrawn
Conditions
Diurnal Enuresis
Interventions
Behavioral: Constipation behavioral therapy
Behavioral: Urotherapy
First Posted Date
2015-01-13
Last Posted Date
2018-04-11
Lead Sponsor
Rabin Medical Center
Registration Number
NCT02336906
Locations
🇮🇱

Institute of Gastroenterology, Nutrition, and Liver Diseases; Schneider Children's Medical Center of Israel, Petach Tikva, Israel

Urotherapy vs. Urotherapy With Constipation Treatment for Nocturnal Enuresis

Phase 4
Withdrawn
Conditions
Nocturnal Enuresis
Interventions
Behavioral: Constipation behavioral therapy
Behavioral: Urotherapy
First Posted Date
2015-01-13
Last Posted Date
2018-04-11
Lead Sponsor
Rabin Medical Center
Registration Number
NCT02337413
Locations
🇮🇱

Institute of Gastroenterology, Nutrition and Liver Diseases; Schneider Children's Medical Center of Israel, Petach Tikva, Israel

Improvement of Tolerance of Bowel Cleansing Before Colonoscopy in Diabetic Patients

Phase 3
Completed
Conditions
Colonic Diseases
Diabetes Mellitus
Interventions
Drug: PEG-ascorbate 2L
First Posted Date
2014-11-21
Last Posted Date
2017-02-23
Lead Sponsor
Parc de Salut Mar
Target Recruit Count
158
Registration Number
NCT02297399
Locations
🇪🇸

Hospital del Mar, Barcelona, Spain

🇪🇸

Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain

Bowel Preparation for Colonoscopy in the Elderly

Phase 4
Completed
Conditions
Bowel Preparation
Colonoscopy
Interventions
First Posted Date
2014-11-13
Last Posted Date
2016-02-24
Lead Sponsor
Kyunghee University Medical Center
Target Recruit Count
230
Registration Number
NCT02290093
Locations
🇰🇷

Hanyang University Guri Hospital, Guri, Korea, Republic of

🇰🇷

Kyung Hee University Hospital, Seoul, Korea, Republic of

🇰🇷

Kangbuk Samsung Hospital, Seoul, Korea, Republic of

Safety of Total Daily Doses of Polyethylene Glycol (PEG) 400 Administered Orally to Healthy Male Human Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2014-10-09
Last Posted Date
2014-10-09
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
64
Registration Number
NCT02260076

A Safety, Tolerability and Preliminary Pharmacokinetics of BILR 355 BS Single-rising Dose Study in Healthy Male Volunteers

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: BILR 355 BS
First Posted Date
2014-10-02
Last Posted Date
2014-10-02
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
54
Registration Number
NCT02254538

A Phase III Study With FE 999169 Versus Niflec for Colon Cleansing

Phase 3
Completed
Conditions
Colon Cleansing in Preparation for Colonoscopy
Interventions
First Posted Date
2014-08-13
Last Posted Date
2017-07-17
Lead Sponsor
Ferring Pharmaceuticals
Target Recruit Count
637
Registration Number
NCT02215954
Locations
🇯🇵

Investigational site, Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath